Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $1,285,401.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $11.53, for a total transaction of $57,650.00.
• On Wednesday, July 10th, Richard Nolan Townsend sold 26,969 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $16.50, for a total transaction of $444,988.50.

Lexeo Therapeutics Price Performance

LXEO stock opened at $10.24 on Thursday. Lexeo Therapeutics, Inc. has a 1 year low of $9.00 and a 1 year high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. The firm has a market capitalization of $337.36 million and a PE ratio of -0.46. The business has a 50 day simple moving average of $12.43 and a 200-day simple moving average of $13.92.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.64). Equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds have recently modified their holdings of LXEO. Janus Henderson Group PLC boosted its holdings in Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after purchasing an additional 210,047 shares during the last quarter. Blackstone Inc. purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at approximately $9,342,000. BNP Paribas Financial Markets acquired a new position in Lexeo Therapeutics in the first quarter valued at approximately $75,000. American International Group Inc. purchased a new position in Lexeo Therapeutics in the first quarter worth approximately $79,000. Finally, Vanguard Group Inc. increased its stake in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after acquiring an additional 65,573 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LXEO. Robert W. Baird initiated coverage on shares of Lexeo Therapeutics in a research note on Thursday, June 13th. They set an “outperform” rating and a $28.00 target price for the company. Baird R W upgraded Lexeo Therapeutics to a “strong-buy” rating in a research note on Thursday, June 13th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright reduced their price objective on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $22.14.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.